WO2005060964A1 - Novel use of ion channel active compound, meperidine, to mediate process of accelerated wound healing - Google Patents

Novel use of ion channel active compound, meperidine, to mediate process of accelerated wound healing Download PDF

Info

Publication number
WO2005060964A1
WO2005060964A1 PCT/US2003/039948 US0339948W WO2005060964A1 WO 2005060964 A1 WO2005060964 A1 WO 2005060964A1 US 0339948 W US0339948 W US 0339948W WO 2005060964 A1 WO2005060964 A1 WO 2005060964A1
Authority
WO
WIPO (PCT)
Prior art keywords
meperidine
wound healing
ion channel
pain
surgical
Prior art date
Application number
PCT/US2003/039948
Other languages
French (fr)
Inventor
Alfred A. Ms Dds Nickel
Original Assignee
Nickel Alfred A Ms Dds
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/318,940 priority Critical patent/US20040116470A1/en
Priority claimed from US10/318,940 external-priority patent/US20040116470A1/en
Application filed by Nickel Alfred A Ms Dds filed Critical Nickel Alfred A Ms Dds
Priority to PCT/US2003/039948 priority patent/WO2005060964A1/en
Priority to EP03787302A priority patent/EP1699457A4/en
Publication of WO2005060964A1 publication Critical patent/WO2005060964A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/17ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection

Definitions

  • T ie present invention discloses a method that accelerates human wound healing as demonstrated in the alteration of post surgical events following exodontias and oral surgery performed by an oral and maxillofacial surgeon.
  • Figure 1 represents the ion channel accelerated wound healing process.
  • Figure 2 represents design components of molecular carrier.
  • Meperidine trade name Demerol
  • Meperidine is available for medical use as an agent to support anesthesia and relief of moderate to severe pain. 1 Approximately six years ago, this agent was noted to clinically relieve oral surgical pain from extractions when infiltrated subcutaneously in the oral cavity buccal or labial to the extraction site. Meperidine is recognized as a deep bone receptor blockade agent and local anesthetic receptor blockade agent in both animal studies and in human obstetrical care. 2 ⁇ 45 Additionally meperidine is a central nervous system analgesic and amnesic agent.
  • meperidine is delivered in a standard insulin syringe pre-loaded with 40 mg meperidine in preservative-free solution (available as lcc (100 mg) ampules or lcc (100 mg) muitidose vials). If a solution containing a preservative is used, excessive facial edema and tissue necrosis is observed clinically. Consequently, early on, the use of meperidine for oral surgery was standardized as preservative-free and limited to low doses of 5-20 mg per extraction site with a maximum of 120 mg for any oneifldividual. Nausea-is rare if the total body dose is under 120 mg.
  • the surgical procedure also involves the concurrent tise of intravenous barbituates (hexibarbitol), 0.2 mg atropine, 2 mg dexamethasone, and concurrent use of 100% oxygen.
  • Nitrous oxide 20-40%, may be used intermittently during the case to assist the phobic dental patient through the procedure. Additionally each patient is encouraged to take orally 2000 units of vitamin C (adult dose) the day before surgery and 2000 units per day for 5 days postoperatively.
  • the intravenous and inspired gas agents comprise a standard regime that has been used consistently for 28 years in this private oral surgery practice, and this method of anesthetic management was published in 1993 in articles focusing on paresthesia and post-operative sequelae.
  • meperidine No periodontal ligament or intraosseous injection of meperidine is used. Immediate postoperative pain management is unique using meperidine infiltration. All conscious patients are fully functional in the oral cavity. They can immediately talk clearly, drink fluids, and eat because the "numbness" resulting from the use of traditional local anesthetics is not present. Meperidine is a pain ion channel blockade agent without any marked clinical numbness. However, paresthesia can occur demonstrating that meperidine acts and can get "stuck" in the ion channel. Some patients on regaining consciousness require oral narcotic management, some oral ibuprofen management, some aspirin, some require nothing at all.
  • an extraction socket will have formed a complete clot with no further bleeding from that location during the case. This rapid clotting during surgery is seen three minutes after injection of meperidine. (If a patient has a pre-existing bleeding disorder, early clotting is not seen; but in the case of a patient with a factor deficiency disease, clotting was satisfactory for discharge 15 minutes after suturing.) Initially this lack of intraoperative bleeding was thought to be due to the elimination of the vasodilating aminobenzene and thiophene local anesthetics, however further observation of this effect suggests that it is more probably the result of the ihc ease r mirttfacetMlar metabolic ra1es 7" caused by the metabolites of meperidine produced by the ion channel.
  • the molecular ion channel serves as a receptor that can also include a site for enzyme hydrolysis.
  • the meperidine molecule has an affinity to the ion channel site.
  • the meperidine molecule Once inside the channel, it will immediately undergo hydrolysis of its esterfied alcohol bond in the same way as other local anesthetics do.
  • the meperidine molecule then has the head (ring structure) and tail (esterized alcohol) structure that characterizes known aminobenzene and thiophene local anesthetics.
  • the residual ring structure has the potential to reduce to pyridoxal phosphate analogues (Vitamin B-6 analogues) at an intracellular level of activity.
  • Vitamin B-6 analogues inpact alpha-amino add degradation to high metabolic fuels.
  • Alpha-amino adds in addition to their role as monomeric units, are energy metabolites and precursors of many biologically important nitrogen-containing compounds, notably heme, physiologically active amines, glutathione, nudeotides, and nucleotide coenzymes...
  • Vitamin B-ix analogues otrfd dictate rapid ⁇ ceflutarmetabo!ie rates ⁇ v ⁇ a coenzyme activity.
  • Concurrent usage of oxygen during the surgical procedure would then provide an environment favorable to a rapid wound repair mechanism mediated by Vitamin B-6 analogues via known coenzyme pathways similar to those induced by hyperbaric oxygen but brought about through a biochemical hypermetabolic state instead.
  • the Vitamin B-6 analogues can elevate action potential thresholds to reduce transmission of neuron pain impulses.
  • the desirable phenomena of clinically observable rapid wound healing, rapid blood clotting, lack of cardiac arrythmias, and minimization of post-operative pain are explained by the production of ion channel metabolites from meperidine.
  • the meperidine molecule can thus first impede ion channel function with its local anesthetic component; and then, through the coenzyme activity of its intracellular molecular component produced in its metabolism in the ion channel, it can cause rapid surgical wound healing. Further analysis of these actions of meperidine would allow the design of new molecules which, having an affinity to the ion channel in the cell wall, could introduce agents to promote wound healing directly into cells at the site of injury.
  • Vitamin B-6 powder suspended in a transdermal transport cream.
  • An example Of strch a transdermal cream w ⁇ uld-be soy le ⁇ thin mis ⁇ pr ⁇ pylpairratate 50/56, pluronic F127 (poloxamer 407 NF) 20% in water, B-5 powder 5%, B-6 powder 30%.
  • transdermal cream containg B-5 (5%) and B-6 (30%) after the injury resulted in compete cessation of pain in 8 minutes, blood blister hematoma completely resolved in 12-14 hours, return of function and normal tissue contours in 48 hours. Normally such an injury to the thumb from a hammer blow may take up to 3 months to heal to the degree seen in 48 hours after use of the B-5, B-6 transdermal cream.
  • Figures 1 and 2 gives a novel method of vitamin delivery to human tissue that results in clear cut accelerated wound healing.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Materials For Medical Uses (AREA)

Abstract

The present invention discloses a method of employing ion channel active to compounds to deliver metabolism-enhancing molecules within the cell to promote rapid wound healing. It also develops a delivery kit for meperidine as a local anesthetic and wound healing accelerant for dental surgical use. And meperidine thus serves as a pattern for future design of novel wound healing compounds. Secondly, a topical cream consisting of high dose B-6/B-5 in a transdurmal transport medium accomplishes the same result of accelerated wound healing.

Description

SPECIFICATION 1. TITLE OF THE INVENTION Novel Use of Ion Channel Active Compound, Meperidine, to Mediate Process of Accelerated Wound Healing.
Inventor: Alfred A. Nickel, MS, DDS 4663 Jenkinson Circle Pollock Pines, CA 95726
2.REPERENCES
U.S. PATENT DOCUMENTS
5,780,242 7/14/98 Nickel AA 5,776,859 7/7/98 Nickel AA
OTHER PUBLICATIONS
1. Meperidine pkg insert. Manufactured by Baxter Healthcare Corporation (12, 2001). 2. Jaffe RA, Rowe MA. "A comparison of local anesthetic effects of meperidine, fentanyl, and sufentanil on dorsal root axons". Anesth Analg 83:776-81 (1996). 3. Hassan HG, Youssef H., Renck H. "Duration of Experimental nerve block by combinations of local anesthetic agents". Ada Anesthesiol Scand 37:70-74 (1993). 4. Armstrong PJ, Morton CP, Nimmo AF. "Pethidine has a local anesthetic action on peripheral nerves in vivo. Addition to prilocaine 0.25% for intravenous regional anaesthesia in volunteers". Anesthesia 48(5):382-6 (5/1993). 5. Nelson KM, Vincent RG, et al. "Intraoperative intercostals nerve freezing to prevent postthoracotomy pain". Arch Int Pharmacodyn Ther 251 (1): 150- 65-(5, 1981). 6. Nickel AA. "A retrospective study of paresthesia of the dental alveolar nerves". Anesth Prog 37:42-45 (1990). 7. Voet D, Voet J. Biochemistry, John Wiley & Sons, p 727 (1995). 8. Niaspan pkg insert. Manufactured by Kos Pharmaceuticals, Inc. 400025/0600 (1999). 9. Goldstein A, Aronow L, Kal an, S. Principles of Drug Action, Harper & Rowe, p 55 (1968). 10. Mahler HR, Cordes EH. Biological Chemistry, Harper & Row, p 341 (1966). 11. Willimann H, Walde P, Luisi PL, Gazzaniga A, Stroppolo F. "Lecithin Organogel as Matrix for Transdermal Transport of Drugs". Journal of Pharmaceutical Sciences 81(9): pp 871-874 (9/92).
3. STATEMENT OF FEDERALLY SPONSORED RESEARCH /DEVELOPMENT: not applicable.
4. REFERENCE TO "SEQUENCE LISTINC" not applicable. 5. BACKGROUND OF THE INVENTION
Normal healing after surgical and third molar procedures can result in painful sequelae up to 14 days after surgery, which frequently require after-hour intervention by the surgeon. Among these sequelae are localized osteotitis (dry socket), trismus, facial edema, and protracted bleeding. For the purposes of this invention, the definition of "healed extraction site" will be a surgical wound that presents as normal dinjcal dental ridge architecture with pinjς gingivaj tissue and without classic granulation tissue, erythema, or edema. T ie present invention discloses a method that accelerates human wound healing as demonstrated in the alteration of post surgical events following exodontias and oral surgery performed by an oral and maxillofacial surgeon. The injection of a specific ion channel active compound during surgery for anesthesia management over a five year period revealed a pronounced acceleration of healing of the surgical wound over that seen in the absence of that ion channel active compound. For 15% of patients, healing occurred in 1 day; for 80% in 3-4 days; and for 5% 5-10 days. These findings have led to the novel concept of using an ion channel active chemical, an anesthetic, to act as a carrier of a desired molecular component into the ion channel in order to facilitate the entry of the molecular component into the cell itself and give it direct access to the intracellular metabolic machinery where it can act to accelerate rapid surgical wound healing. 6. BRIEF SUMMARY OF THE INVENTION
Unusually rapid postoperative healing of surgical wounds has demonstrated the benefits of a method of using meperidine to function in the receptor ion channel to cause a blockade of deep bone pain and the pain controlled by local anesthetics and then to cause the desired acceleration of wound healing by virtue of intracellular metabolic stimulation.
7. BRIEF DESCRIPTION OF DRAWINGS
Figure 1 represents the ion channel accelerated wound healing process. Figure 2 represents design components of molecular carrier.
8. DETAILED DESCRIPTION OF THE INVENTION
Meperidine, trade name Demerol, is available for medical use as an agent to support anesthesia and relief of moderate to severe pain.1 Approximately six years ago, this agent was noted to clinically relieve oral surgical pain from extractions when infiltrated subcutaneously in the oral cavity buccal or labial to the extraction site. Meperidine is recognized as a deep bone receptor blockade agent and local anesthetic receptor blockade agent in both animal studies and in human obstetrical care.2Λ45 Additionally meperidine is a central nervous system analgesic and amnesic agent. For subcutaneous injection buccal or labial to extraction sites, meperidine is delivered in a standard insulin syringe pre-loaded with 40 mg meperidine in preservative-free solution (available as lcc (100 mg) ampules or lcc (100 mg) muitidose vials). If a solution containing a preservative is used, excessive facial edema and tissue necrosis is observed clinically. Consequently, early on, the use of meperidine for oral surgery was standardized as preservative-free and limited to low doses of 5-20 mg per extraction site with a maximum of 120 mg for any oneifldividual. Nausea-is rare if the total body dose is under 120 mg. The surgical procedure also involves the concurrent tise of intravenous barbituates (hexibarbitol), 0.2 mg atropine, 2 mg dexamethasone, and concurrent use of 100% oxygen. Nitrous oxide, 20-40%, may be used intermittently during the case to assist the phobic dental patient through the procedure. Additionally each patient is encouraged to take orally 2000 units of vitamin C (adult dose) the day before surgery and 2000 units per day for 5 days postoperatively. The intravenous and inspired gas agents comprise a standard regime that has been used consistently for 28 years in this private oral surgery practice, and this method of anesthetic management was published in 1993 in articles focusing on paresthesia and post-operative sequelae.6 In these 28 years, the only change in this method of patient anesthetic care has been, since March 1997, the elimination of aminobenzene local anesthetics and the substitution of meperidine as the "local" by subcutaneous infiltrating injection adjacent to and in the immediate vicinity of the surgical site. (A thiophene local anesthetic has been used on rare occasions.) The insulin syringe has a short needle (28 gauge x 1/2 inch), preventing its use to achieve the traditional dental nerve block and thus also preventing the development of post-operative paresthesia which has been noted to occur in nerve block techniques with meperidine. The infiltration process usually includes 5-15 mg in the dental sulcus with 2-3 mg infused in the attached gingiva. No periodontal ligament or intraosseous injection of meperidine is used. Immediate postoperative pain management is unique using meperidine infiltration. All conscious patients are fully functional in the oral cavity. They can immediately talk clearly, drink fluids, and eat because the "numbness" resulting from the use of traditional local anesthetics is not present. Meperidine is a pain ion channel blockade agent without any marked clinical numbness. However, paresthesia can occur demonstrating that meperidine acts and can get "stuck" in the ion channel. Some patients on regaining consciousness require oral narcotic management, some oral ibuprofen management, some aspirin, some require nothing at all. Each surgical patient is telephoned the evening of surgery to monitor progress and many of them report at this time that they have not required the post-operative prescribed narcotics because they are not experiencing pain. Patients are sutured for management of bleeding, but with meperidine something unusual occurs during the surgery. With four impacted third molars, for example, prior to March 1997, expected blood loss was 70-150 cc per case. After March 1997, when meperidine was used as the local anesthetic instead of an aminobenzene, blood loss per case dropped to 2-10 cc routinely and rarely went over 20 cc. Since the surgical area is not flooded with blood, the surgeon is able to clearly visualize the bony exodontia sites. Additionally, within 2-5 minutes, an extraction socket will have formed a complete clot with no further bleeding from that location during the case. This rapid clotting during surgery is seen three minutes after injection of meperidine. (If a patient has a pre-existing bleeding disorder, early clotting is not seen; but in the case of a patient with a factor deficiency disease, clotting was satisfactory for discharge 15 minutes after suturing.) Initially this lack of intraoperative bleeding was thought to be due to the elimination of the vasodilating aminobenzene and thiophene local anesthetics, however further observation of this effect suggests that it is more probably the result of the ihc ease r mirttfacetMlar metabolic ra1es7"caused by the metabolites of meperidine produced by the ion channel. Postoperative pain management over 5 years has been greatly simplified since the introduction of meperidine as the local anesthetic because "dry sockets" have disappeared from the practice. Before the dry socket can occur on day 5 postoperatively, 80% of patients have healed. Even as early as twenty-four hours after surgery, some patients have presented with a dental alveolar ridge that is pink with no evidence of an extraction socket and no tissue edema or redness suggestive of a surgical procedure. A majority of cases (60-80%) present 3-4 days post surgery with pink surgical site tissue including the mucoperiostial flap. These pink, non-ery themic wound sites clinically appear similar to patients having treatment in a hyperbaric oxygen chamber, but no hyperbaric care has been given. Meperidine then acts to promote metabolic rates favorable to rapid tissue repair. In these 5 years there have been no post-operative infections and no cases of trismus or temeromandibular joint dysfunction requiring care with physical therapy, Intraoperatively cardiac monitored arrythmias have disappeared.8 Laryngiospasms requiring the use of muscle paralyzing agents are not experienced. This rapid wound healing process was noted initially in the Walnut Creek, California oral surgical practice in March 1997. In April 2001, the surgeon relocated his home more than 120 miles east of Walnut Creek. For 10 months, through February 2002, based on the observed rapid clotting and wound healing noted with meperidine, the surgeon drove 2.5 hours in the morning to Walnut Creek, did 3-4 surgical procedures, and then drove 2.5 hours home the same day. No post-operative bleeding or wound management problems developed even though prophylactic antibiotics were not always Used. At the new practice location in El Dorado Hills, California, (1 hour from home), after 7 months, no post-operative wound management problems have required a return to the office. In fact, the beeper service since March 1997 for after hour patient needs has been silent. Staff and patient population both in the El Dorado Hills practice have become acutely aware of the rapid post-operative healing as seen in the Walnut Creek location. As described in U.S. patents 5,780,242 and 5,776,859, the molecular ion channel serves as a receptor that can also include a site for enzyme hydrolysis. The meperidine molecule has an affinity to the ion channel site.9 Once inside the channel, it will immediately undergo hydrolysis of its esterfied alcohol bond in the same way as other local anesthetics do. The meperidine molecule then has the head (ring structure) and tail (esterized alcohol) structure that characterizes known aminobenzene and thiophene local anesthetics. The residual ring structure has the potential to reduce to pyridoxal phosphate analogues (Vitamin B-6 analogues) at an intracellular level of activity. "Pyridoxal phosphate is the most striking of the known coenzymes in terms of the multiplidty of different enzymatic reactions that are dependent on its presence."10 By coenzyme function Vitamin B-6 analogues inpact alpha-amino add degradation to high metabolic fuels. "Alpha-amino adds, in addition to their role as monomeric units, are energy metabolites and precursors of many biologically important nitrogen-containing compounds, notably heme, physiologically active amines, glutathione, nudeotides, and nucleotide coenzymes... amino adds are also precursors of glucose, fatty adds, and ketone bodies, and are therefore metabolic fuels."7 Thus sudden high intracellular levels of Vitamin B-ix analogues otrfd dictate rapid~ceflutarmetabo!ie rates~vτa coenzyme activity. Concurrent usage of oxygen during the surgical procedure would then provide an environment favorable to a rapid wound repair mechanism mediated by Vitamin B-6 analogues via known coenzyme pathways similar to those induced by hyperbaric oxygen but brought about through a biochemical hypermetabolic state instead. The Vitamin B-6 analogues can elevate action potential thresholds to reduce transmission of neuron pain impulses. The desirable phenomena of clinically observable rapid wound healing, rapid blood clotting, lack of cardiac arrythmias, and minimization of post-operative pain are explained by the production of ion channel metabolites from meperidine. The meperidine molecule can thus first impede ion channel function with its local anesthetic component; and then, through the coenzyme activity of its intracellular molecular component produced in its metabolism in the ion channel, it can cause rapid surgical wound healing. Further analysis of these actions of meperidine would allow the design of new molecules which, having an affinity to the ion channel in the cell wall, could introduce agents to promote wound healing directly into cells at the site of injury. Once present in the wall, the molecule would be metabolized to its pre-designed molecular component (Vitamin B analog) capable of targeting rapid intracellular metabolism and cell repair processes without causing changes in the DNA that might negatively alter cellular architecture. Referring to Figures 1 and 2, another product that has activity in humans or animals to reduce swelling, hematoma, and post-surgical pain consists of Vitamin B-6 powder suspended in a transdermal transport cream. An example Of strch a transdermal cream wσuld-be soy leσthin misσprσpylpairratate 50/56, pluronic F127 (poloxamer 407 NF) 20% in water, B-5 powder 5%, B-6 powder 30%. π Applying a small amount of this cream to the outside of a patient's oral surgical site 4 times daily reduces fadal edema in 36-48 hours instead of 5-8 days. Indurated hematoma present in the edema can see resolution in 14-18 hours rather than 5-8 days. Finally, patients report lack of postoperative pain compatible with the theory represented in Figure I such that the psychological remorse normally resulting from the experience of chronic moderate surgical pain is gone. Another example of this cream's ability to accelerate healing is demonstrated in its use after a hammer blow to the human thumb which produced subdermal "blood" blister, pulsating pain, and nail damage. Application of a transdermal cream containg B-5 (5%) and B-6 (30%) after the injury resulted in compete cessation of pain in 8 minutes, blood blister hematoma completely resolved in 12-14 hours, return of function and normal tissue contours in 48 hours. Normally such an injury to the thumb from a hammer blow may take up to 3 months to heal to the degree seen in 48 hours after use of the B-5, B-6 transdermal cream. Thus analysis of Figures 1 and 2 gives a novel method of vitamin delivery to human tissue that results in clear cut accelerated wound healing.

Claims

9. CLAIMSI claim the following in this invention:
1. I claim the use of meperidine as a molecular carrier of Vitamin B-6 analogues to cause acceleration of wound healing by virtue of intracellular metabolic stimulus in humans and animals (Figure 1).
2. I claim a delivery kit consisting of insulin syringes (28 gauge by 1 / 2") arid one ampule"preservative-ffee meperidine (lOOϋig/cc) with instructions for use.
3. I claim the right to design novel pharmaceuticals capable of having a multiphasic purpose of first seeking out the ion channel and second causing intracellular metabolic events leading to rapid clinical repair of wounds and /or pain control (Figure 2).
4. I claim the use of meperidine in the absence of aminobenzene and thiophene local anesthetics to reduce blood loss during and after surgery.
5. I claim the use of meperidine as a local anesthetic delivered in a cartridge designed for dental use.
6. I claim the use in humans or for veterinary care of B-6 or demerol in a transdermal transport cream or oral gel or opthmalogic ointment applied in the proximity of a surgical procedure or wo ind to rapidly resolve hematoma and tissue edema and reduce or eliminate post- traumatic pain, espedally deep, throbbing, surgical wound pain (Figure 1). The results from application of B-6 in the wound area cannot be obtained by oral dose usage and are novel to Demerol or to B-6 in a transport vehide gel or cream
PCT/US2003/039948 2002-12-16 2003-12-16 Novel use of ion channel active compound, meperidine, to mediate process of accelerated wound healing WO2005060964A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/318,940 US20040116470A1 (en) 2002-12-16 2002-12-16 Novel use of ion channel active compound, meperidine, to mediate process of accelerated wound healing
PCT/US2003/039948 WO2005060964A1 (en) 2002-12-16 2003-12-16 Novel use of ion channel active compound, meperidine, to mediate process of accelerated wound healing
EP03787302A EP1699457A4 (en) 2003-12-16 2003-12-16 Novel use of ion channel active compound, meperidine, to mediate process of accelerated wound healing

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/318,940 US20040116470A1 (en) 2002-12-16 2002-12-16 Novel use of ion channel active compound, meperidine, to mediate process of accelerated wound healing
PCT/US2003/039948 WO2005060964A1 (en) 2002-12-16 2003-12-16 Novel use of ion channel active compound, meperidine, to mediate process of accelerated wound healing

Publications (1)

Publication Number Publication Date
WO2005060964A1 true WO2005060964A1 (en) 2005-07-07

Family

ID=56290512

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/039948 WO2005060964A1 (en) 2002-12-16 2003-12-16 Novel use of ion channel active compound, meperidine, to mediate process of accelerated wound healing

Country Status (1)

Country Link
WO (1) WO2005060964A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530502B2 (en) 2005-12-30 2013-09-10 Dr. N's Health Care Products, Llc Application methods to rapidly alter disease and injury states using molecular transport of B6

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BARAKA ET AL: "Epidural meperidine-bupivacaine for obstetric analgesia", ANESTHESIA AND ANALGESIA, vol. 61, no. 8, 1982, pages 652 - 656, XP002985057 *
See also references of EP1699457A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530502B2 (en) 2005-12-30 2013-09-10 Dr. N's Health Care Products, Llc Application methods to rapidly alter disease and injury states using molecular transport of B6

Similar Documents

Publication Publication Date Title
US20080214506A1 (en) Novel use of ion channel active compound, meperidine, to mediate process of accelerated wound healing
Barber et al. The effectiveness of an anesthetic continuous-infusion device on postoperative pain control
Watson et al. Use of anti‐inflammatory and analgesic drugs in dogs and cats
EP1809329B1 (en) Sustained local anesthetic composition containing saib
US10143685B2 (en) Parenteral and topical compositions for pain
US20100280069A1 (en) Controlled release local anesthetic for post dental surgery and method of use
Loughran et al. Unilateral retrobulbar hematoma following maxillary nerve block in a dog
US8142799B2 (en) High potency clinical anti-craving treatment and method of use
JP2007502866A (en) Implantable polymer device for sustained release of nalmefene
Osenbach et al. Neuraxial infusion in patients with chronic intractable cancer and noncancer pain
Hammer et al. Perineuromal stimulation in the treatment of occipital neuralgia: a case study
Massaro Liposomal bupivacaine: A long-acting local anesthetic for postsurgical analgesia.
Sahoo et al. Botox In Gummy Smile-A Review.
WO2005060964A1 (en) Novel use of ion channel active compound, meperidine, to mediate process of accelerated wound healing
EP1699457A1 (en) Novel use of ion channel active compound, meperidine, to mediate process of accelerated wound healing
Hulse et al. Use of oral and implantable naltrexone in the management of the opioid-impaired physician
US20160101093A1 (en) Methods for the treatment of premature ejaculation
Srampickal et al. How effective is periarticular drug infiltration in providing pain relief and early functional outcome following total hip arthroplasty?
RU2367424C1 (en) Technique for anesthesia following minimally invasive abdominal surgeries
Reuben et al. Preemptive multimodal analgesia for anterior cruciate ligament surgery/Reply
Hosny et al. Response of intractable post herpetic neuralgia to intrathecal baclofen
Milch Neuropathic pain: implications for the surgeon
McBride et al. Successful treatment of a chronic facial abscess using a prolonged release antibiotic copolymer in a golden lion tamarin (Leontopithecus rosalia)
Hacker et al. Total knee arthroplasty pain management with HTX-011 as the foundation of a multimodal analgesic regimen results in low incidence of severe pain
Kakei et al. Efficacy of Ibuprofen Gargle for Postoperative Pain After Mandibular Third Molar Extraction: A Phase II, Placebo-Controlled, Double-Blind, Randomized Crossover Trial

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003787302

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003787302

Country of ref document: EP